SCHEMBL268802

SCHEMBL268802

COC(=O)c1ccsc1NC(=O)c1cccc(CN(C)C)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.67
TDP1 Q9NUW8 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
KMT2A Q03164 2/20 0.57
MAPT P10636 2/20 0.55
MEN1 O00255 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
POLB P06746 1/20 0.48
FLT3 P36888 1/20 0.47
MAPK10 P53779 2/20 0.47
ROCK2 O75116 3/20 0.46
CYP3A4 P08684 2/20 0.46
ALDH1A1 P00352 1/20 0.46
ALOX12 P18054 1/20 0.46
MAPK8 P45983 2/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17859660 0.89 KDM4E (0.72) KDM4ETDP1L3MBTL1KMT2AMAPT
SCHEMBL267882 0.87 KDM4E (0.69) KDM4ETDP1L3MBTL1KMT2AMAPT
SCHEMBL265903 0.83 KDM4E (0.47) KDM4ETDP1L3MBTL1KMT2AMAPT
SCHEMBL4703988 0.80 KDM4E (1.00) KDM4ETDP1L3MBTL1KMT2AMAPT
SCHEMBL165622 0.78 LOXL2 (0.66) KDM4EKMT2AMAPTMEN1SMN1; SMN2
SCHEMBL267190 0.74 FLT3 (0.81) KDM4ETDP1L3MBTL1KMT2AMAPT
SCHEMBL31661836 0.73 KDM4E (0.71) KDM4ETDP1L3MBTL1KMT2AMAPT
SCHEMBL267344 0.73 NPC1 (0.44) KDM4EKMT2AMAPTMEN1SMN1; SMN2
SCHEMBL7398052 0.73 KMT2A (1.00) KDM4ETDP1L3MBTL1KMT2AMAPT
SCHEMBL6581113 0.72 ALDH1A1 (0.54) KDM4EKMT2AMAPTMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KDM4E 4468/4885TDP1 4744/4885L3MBTL1 934/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KDM4E 4535/4885TDP1 4604/4885L3MBTL1 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.